Publications & Conference Proceedings
Featured iNKT cell publications
Cancer Cell Research
8 OCT 2018
Enhanced Anti-lymphoma Activity of CAR19-iNKT Cells Underpinned by Dual CD19 and CD1d Targeting
ScienceDaily
9 OCT 2018
Supercharged natural killer cells may hold promise for cancer
Nature Communications
2 JAN 2024
Conference proceedings
American Association of Cancer Research (AACR) Annual Meeting 2023
April 2023
Engineering allogeneic ‘off-the-shelf’ CD19-directed CAR-iNKT cells without additional genetic manipulations for the treatment of hematological malignancies.
65th American Society of Hematology (ASH) Annual Meeting
December 2023
Arovella’s research collaborators from Imperial College London presented new data using Arovella’s CAR-iNKT cell therapy platform.
American Association of Cancer Research (AACR) Annual Meeting 2024
April 2024
Allogeneic CD19-directed CAR-iNKT cells and their associated phenotypic subsets for the treatment of CD19+ hematological malignancies.
Clinical use of iNKT cells
26 NOV 2020 | Nature Medicine
Anti-GD2 CAR-NKT cells in patients with relapsed or refractory neuroblastoma: an interim analysis
15 JUL 2017 | Clinical Cancer Research
Adoptive Transfer of Invariant NKT Cells as Immunotherapy for Advanced Melanoma: A Phase I Clinical Trial
26 APR 2012 | Journal of Clinical Immunology
Accumulation of Activated Invariant Natural Killer T Cells in the Tumor Microenvironment after a-Galactosylceramide-Pulsed Antigen Presenting Cells
1 AUG 2011 | Clinical Cancer Research
Comparison of Clinical and Immunological Effects of Intravenous and Intradermal Administration of α-GalactosylCeramide (KRN7000)-Pulsed Dendritic Cells
MAR 2011 | Clinical Immunology
Induction of NKT cell-specific immune responses in cancer tissues after NKT cell-targeted adoptive immunotherapy
FEB 2011 | Cancer Immunology Immunotherapy
Migration and immunological reaction after the administration of αGalCer-pulsed antigen-presenting cells into the submucosa of patients with HNC
15 FEB 2009 | The Journal of Immunology
A Phase I-II Study of α-Galactosylceramide-Pulsed IL-2/GM-CSF-Cultured PBMCs in Patients with Advanced and Recurrent NSCLC
MAR 2008 | Cancer Immunology Immunotherapy
Phase I study of α-galactosylceramide-pulsed antigen presenting cells administration to the nasal submucosa in unresectable or recurrent HNC
15 OCT 2006 | Clinical Cancer Research
A Phase I Study of In vitro Expanded Natural Killer T Cells in Patients with Advanced and Recurrent Non–Small Cell Lung Cancer
2 MAY 2005 | The Journal of Experimental Medicine
Sustained expansion of NKT cells and antigen-specific T cells after injection of a-galactosyl-ceramide loaded mature dendritic cells in cancer patients
1 MAR 2005 | Clinical Cancer Research
A Phase I Study of a-Galactosylceramide (KRN7000)–Pulsed Dendritic Cells in Patients with Advanced and Recurrent NSCLC
15 JAN 2004 | Blood
Therapeutic activation of Vα24+Vβ11+ NKT cells in human subjects results in highly coordinated secondary activation of acquired and innate immunity
8 DEC 2002 | Clinical Cancer Research
A Phase I Study of the Natural Killer T-Cell Ligand α-Galactosylceramide (KRN7000) in Patients with Solid Tumors
iNKT cells protect against graft-versus-host disease
31 JUL 2017 | Frontiers in Immunology
Invariant Natural Killer T Cells As Suppressors of Graft-versus-Host Disease in Allogeneic Hematopoietic Stem Cell Transplantation
31 APR 2017 | Leukemia
Pre-transplant donor CD4− invariant NKT cell expansion capacity predicts the occurrence of acute graft-versus-host disease
7 APR 2016 | Blood
Larger number of invariant natural killer T cells in PBSC allografts correlates with improved GVHD-free and progression-free survival
28 MAY 2015 | Blood
A party of three: iNKT cells in GVHD prevention
28 MAY 2015 | Blood
Third-party CD4+ invariant natural killer Tcells protect from murine GVHD lethality
20 NOV 2014 | Blood
CD4+ invariant natural killer T cells protect from murine GVHD lethality through expansion of donor CD4+CD25+FoxP3+ regulatory T cells
24 MAY 2021 | Blood
Graft invariant natural acutekiller T-cell dose predicts risk of graft-versus-host disease in allogeneic hematopoietic stem cell transplantation
FEB 2010 | Transfusion
Adoptive therapy by transfusing expanded donor murine natural killer T cells can suppress acute graft‐versus‐host disease in allogeneic bone marrow transplantation
1 SEP 2008 | The Journal of Immunology
Human Invariant NKT Cells Display Alloreactivity Instructed by Invariant TCR-CD1d Interaction and Killer Ig Receptors
